Alamar Biosciences Successfully Lists on NASDAQ
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: Newsfilter
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an initial share price of $17 and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to support the company through subsequent Series B and C rounds, holding approximately 19.2% of shares before the IPO, reflecting strong long-term confidence in the company's potential.
- Technological Innovation: Alamar's self-developed NULISA™ technology overcomes design limitations of existing proteomics tools, delivering ultra-high sensitivity and specificity in protein detection, filling critical gaps left by other methods, and paving the way for the future of early disease screening and precision diagnostics.
- Market Penetration: By the end of 2025, the ARGO™ HT system had over 100 units installed across 25 countries, serving more than 300 customers, indicating rapid growth in product market penetration and further solidifying Alamar's leadership position in the global proteomics market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMR
Wall Street analysts forecast ALMR stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 19.760
Low
Averages
High
Current: 19.760
Low
Averages
High
About ALMR
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Ratings Overview
- Goldman Sachs Bullish on Aevex: Goldman Sachs initiates coverage of Aevex (AVEX) with a Buy rating and a $34 price target, based on a 5.4X CY27 EV/Sales, indicating confidence in the company's unique position in the drone market and its growth potential.
- Citi Raises Broadcom Target: Citi raises Broadcom's price target from $475 to $500, applying a 20x multiple to FY28 EPS of $25, reflecting optimism about the company's earnings visibility and maintaining its status as the #1 semiconductor pick for 2026.
- JPMorgan Upgrades Braskem: JPMorgan upgrades Braskem to Overweight from Neutral, citing improved market fundamentals, tighter supply, and strengthened governance post-restructuring, which are expected to enhance profit margins in the chemical sector.
- Evercore Initiates Benitec Coverage: Evercore initiates coverage of Benitec Biopharma with an Overweight rating, highlighting significant upside potential in the rare disease market, suggesting promising investment opportunities ahead.
See More
Alamar Biosciences Q1 Financial Results
- Financial Performance: Alamar Biosciences reported a Q1 GAAP EPS of -$1.74, yet achieved revenues of $26 million, reflecting a robust 98.5% year-over-year growth that underscores the company's strong market potential.
- IPO Dynamics: The firm is experiencing increased cash burn leading up to its IPO, indicating a significant investment in expansion and R&D, which may exert short-term pressure on its financial health.
- Stock Price Movement: Following its IPO, Alamar Biosciences' stock surged by 40%, signaling positive market sentiment regarding its business model and future growth prospects, potentially attracting more investor interest.
- Pricing Strategy: The company successfully priced its upsized IPO at $17 per share, demonstrating market confidence in its valuation while providing necessary capital for future development.
See More
ALAMAR BIOSCIENCES REPORTS Q1 EPS OF $-1.74
- Earnings Per Share (EPS): The reported EPS for Q1 is $-1.74.
- Company Name: The summary pertains to Alamar Biosciences.
See More
ALAMAR BIOSCIENCES INC - Q1 2026 REVENUE INCREASES TO $26.0 MILLION
- Revenue Growth: Alamar Biosciences reported a revenue increase to $26.0 million in Q1 2026.
- Financial Performance: The rise in revenue indicates a positive trend in the company's financial performance.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
April IPO Market Rebounds with $7.3 Billion Raised
- Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
- Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
- Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
- Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
See More
Latest Wall Street Ratings Overview
- Goldman Sachs Bullish on Aevex: Goldman Sachs initiates coverage of Aevex (AVEX) with a Buy rating and a $34 price target, based on a 5.4X CY27 EV/Sales, indicating confidence in the company's unique position in the drone market and its growth potential.
- Citi Raises Broadcom Target: Citi raises Broadcom's price target from $475 to $500, applying a 20x multiple to FY28 EPS of $25, reflecting optimism about the company's earnings visibility and maintaining its status as the #1 semiconductor pick for 2026.
- JPMorgan Upgrades Braskem: JPMorgan upgrades Braskem to Overweight from Neutral, citing improved market fundamentals, tighter supply, and strengthened governance post-restructuring, which are expected to enhance profit margins in the chemical sector.
- Evercore Initiates Benitec Coverage: Evercore initiates coverage of Benitec Biopharma with an Overweight rating, highlighting significant upside potential in the rare disease market, suggesting promising investment opportunities ahead.
See More
Alamar Biosciences Q1 Financial Results
- Financial Performance: Alamar Biosciences reported a Q1 GAAP EPS of -$1.74, yet achieved revenues of $26 million, reflecting a robust 98.5% year-over-year growth that underscores the company's strong market potential.
- IPO Dynamics: The firm is experiencing increased cash burn leading up to its IPO, indicating a significant investment in expansion and R&D, which may exert short-term pressure on its financial health.
- Stock Price Movement: Following its IPO, Alamar Biosciences' stock surged by 40%, signaling positive market sentiment regarding its business model and future growth prospects, potentially attracting more investor interest.
- Pricing Strategy: The company successfully priced its upsized IPO at $17 per share, demonstrating market confidence in its valuation while providing necessary capital for future development.
See More
ALAMAR BIOSCIENCES REPORTS Q1 EPS OF $-1.74
- Earnings Per Share (EPS): The reported EPS for Q1 is $-1.74.
- Company Name: The summary pertains to Alamar Biosciences.
See More
ALAMAR BIOSCIENCES INC - Q1 2026 REVENUE INCREASES TO $26.0 MILLION
- Revenue Growth: Alamar Biosciences reported a revenue increase to $26.0 million in Q1 2026.
- Financial Performance: The rise in revenue indicates a positive trend in the company's financial performance.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
April IPO Market Rebounds with $7.3 Billion Raised
- Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
- Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
- Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
- Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
See More
